Compounds for treating disorders of lipid metabolism and their
preparation
    1.
    发明授权
    Compounds for treating disorders of lipid metabolism and their preparation 失效
    用于治疗脂质代谢紊乱及其制备的化合物

    公开(公告)号:US5773447A

    公开(公告)日:1998-06-30

    申请号:US874255

    申请日:1997-06-13

    CPC分类号: C07D403/04 C07D403/14

    摘要: The present invention relates to tertiary 4-amino-2-ureidopyrimidine-5-carboxamides of formula I: ##STR1## in which R.sup.1 is (C.sub.1 -C.sub.8)-alkyl wherein one or more H are replaced by F; R.sup.2 is selected from the group consisting of F, Cl, Br, H, --O--(C.sub.1 -C.sub.8)-alkyl and (C.sub.1 -C.sub.8)-alkyl, wherein one or more of the H of the alkyls can be replaced by F; R.sup.3 is selected from the group consisting of F, Cl, Br, H, --O--(C.sub.1 -C.sub.4)-alkyl and (C.sub.1 -C.sub.4)-alkyl, wherein one or more of the H of the alkyl can be replaced by F; R.sup.4 is CF.sub.3 or OCF.sub.3 ; and their physiologically tolerable salts. Process for preparing the compounds of formula I are also described. The compounds are suitable for the treatment of disorders of lipid metabolism.

    摘要翻译: 本发明涉及式I的叔-4-氨基-2-脲基嘧啶-5-甲酰胺:一个或多个H被F取代; R 2选自F,Cl,Br,H,-O-(C 1 -C 8) - 烷基和(C 1 -C 8) - 烷基,其中烷基的H中的一个或多个可以被F ; R 3选自F,Cl,Br,H,-O-(C 1 -C 4) - 烷基和(C 1 -C 4) - 烷基,其中烷基的H中的一个或多个可以被F ; R4是CF3或OCF3; 及其生理上可耐受的盐。 还描述了制备式I化合物的方法。 该化合物适用于治疗脂质代谢紊乱。

    Compounds for treating disorders of lipid metabolism and their
preparation
    2.
    发明授权
    Compounds for treating disorders of lipid metabolism and their preparation 失效
    用于治疗脂质代谢紊乱及其制备的化合物

    公开(公告)号:US5939424A

    公开(公告)日:1999-08-17

    申请号:US868991

    申请日:1997-06-04

    CPC分类号: C07D403/04

    摘要: The invention relates to 4-Amino-2-ureidopyrimidine-5-carboxamides of the formula I ##STR1## in which R.sup.1 is H or (C.sub.1 -C.sub.8)-alkyl, where one or more H can be replaced by F; R.sup.2 is selected from the group consisting of F, Cl, Br, H, -O-(C.sub.1 -C.sub.8)-alkyl, and -S-(C.sub.1 -C.sub.8)-alkyl, where the alkyl groups have one or more H replaced by F; R.sup.3 is -O-(C.sub.1 -C.sub.8)-alkyl or -S-(C.sub.1 -C.sub.8)-alkyl, where the alkyl groups have one or more H replaced by F; or R.sup.2 and R.sup.3 together form -O-(C.sub.1 -C.sub.5)-alkylene-O-, where the alkylene portion has one or more H replaced by F; and their physiologically tolerable salts. The invention further provides processes for preparing the compounds of formula I. The compounds are suitable for the treatment of disorders of lipid metabolism.

    摘要翻译: 本发明涉及式I的4-氨基-2-脲基嘧啶-5-甲酰胺,其中R 1为H或(C 1 -C 8) - 烷基,其中一个或多个H可被F取代; R 2选自F,Cl,Br,H,-O-(C 1 -C 8) - 烷基和-S-(C 1 -C 8) - 烷基,其中烷基具有一个或多个H被 F; R 3是-O-(C 1 -C 8) - 烷基或-S-(C 1 -C 8) - 烷基,其中烷基具有一个或多个H被F取代; 或R 2和R 3一起形成-O-(C 1 -C 5) - 亚烷基-O-,其中亚烷基部分具有一个或多个H被F取代; 及其生理上可耐受的盐。 本发明还提供了制备式I化合物的方法。该化合物适用于治疗脂质代谢紊乱。

    Diastereomers of 1-(isopropoxycarbonyloxy) ethyl 3-cephem 4-carboxylate
    6.
    发明授权
    Diastereomers of 1-(isopropoxycarbonyloxy) ethyl 3-cephem 4-carboxylate 失效
    1-(异丙氧基羰基氧基)乙基3-头孢烯-4-羧酸酯的非对映异构体

    公开(公告)号:US5550232A

    公开(公告)日:1996-08-27

    申请号:US447229

    申请日:1995-05-22

    CPC分类号: C07D501/00

    摘要: Enterally absorbable diastereomers of 1-(isopropoxycarbonyloxy)ethyl (6R,7R)-7-[2-(2-aminothiazol-4-yl)-2-(Z)-(methoxyimino)acetamido]-3-(methoxymethyl)-3-cephem-4-carboxylate of the formula I ##STR1## and their physiologically acceptable salts and also diastereomerically pure salts of the compounds of the formula II ##STR2## where HX is a mono- or polybasic acid and where X is an inorganic or organic physiologically acceptable anion, and a process for the preparation of these compounds of the formula I or II, which comprises first precipitating the more sparingly soluble diastereomer of the formula IV in the mixing together of 1 equivalent of a solution of the diastereomer mixture of the formula III with 0.2-2 equivalents of a solution of the acid component HY and separating it off by filtration, then precipitating the more readily soluble diastereomer of the formula IV from the filtration solution, it being possible for the acid component HY to be identical or different in the consecutive partial steps and any desired sequence of addition of different acid components HY being possible, and optionally further purifying the obtained salts by crystallization, are described.

    摘要翻译: 1-(异丙氧羰基氧基)乙基(6R,7R)-7- [2-(2-氨基噻唑-4-基)-2-(Z) - (甲氧基亚氨基)乙酰氨基] -3-(甲氧基甲基)-3 式I的化合物 - 头孢烯-4-羧酸酯及其生理学上可接受的盐以及式II化合物的非对映体纯盐,其中HX是单或多元酸,其中X是无机或有机的 生理学上可接受的阴离子,以及制备这些式I或II化合物的方法,其包括首先将式IV的较微溶的非对映体沉淀在1当量的式(I)的非对映体混合物的溶液中, III与0.2-2当量的酸组分HY的溶液并通过过滤分离,然后从过滤溶液中沉淀出更容易溶解的式IV的非对映异构体,酸组分HY可能相同或不同 在一起 描述了部分步骤和任何期望的不同酸组分HY的加入顺序是可能的,并且任选地通过结晶进一步纯化得到的盐。

    Diastereomers of 1-(isopropoxycarbonyloxy)ethyl 3-cephem-4-carboxylate
and processes for their preparation
    8.
    发明授权
    Diastereomers of 1-(isopropoxycarbonyloxy)ethyl 3-cephem-4-carboxylate and processes for their preparation 失效
    3-头孢烯-4-羧酸1-(异丙氧基羰基氧基)乙酯的非对映异构体及其制备方法

    公开(公告)号:US5614623A

    公开(公告)日:1997-03-25

    申请号:US447249

    申请日:1995-05-22

    CPC分类号: C07D501/00

    摘要: Enterally absorbable diastereomers of 1-(isopropoxycarbonyloxy)ethyl (6R, 7R)-7-[2-(2-aminothiazol-4-yl)-2-(Z)-(methoxyimino)acetamido]-3-(methoxymethyl)-3-cephem-4-carboxylate of the formula I ##STR1## and their physiologically acceptable salts and also diastereomerically pure salts of the compounds of the formula II ##STR2## where HX is a mono- or polybasic acid and where X is an inorganic or organic physiologically acceptable anion, and a process for the preparation of these compounds of the formula I or II, which comprises first precipitating the more sparingly soluble diastereomer of the formula IV in the mixing together of 1 equivalent of a solution of the diastereomer mixture of the formula III with 0.2-2 equivalents of a solution of the acid component HY and separating it off by filtration, then precipitating the more readily soluble diastereomer of the formula IV from the filtration solution, it being possible for the acid component HY to be identical or different in the consecutive steps.

    摘要翻译: 1-(异丙氧羰基氧基)乙基(6R,7R)-7- [2-(2-氨基噻唑-4-基)-2-(Z) - (甲氧基亚氨基)乙酰氨基] -3-(甲氧基甲基)-3 式I的化合物 - 头孢烯-4-羧酸酯及其生理学上可接受的盐以及式II化合物的非对映体纯盐,其中HX是单或多元酸,其中X是无机或有机的 生理学上可接受的阴离子,以及制备这些式I或II化合物的方法,其包括首先将式IV的较微溶的非对映体沉淀在1当量的式(I)的非对映体混合物的溶液中, III与0.2-2当量的酸组分HY的溶液并通过过滤分离,然后从过滤溶液中沉淀出更容易溶解的式IV的非对映异构体,酸组分HY可能相同或不同 在consecu 有步骤。

    Diastereomers of 1-(isopropoxycarbonyloxy)ethyl 3-cephem-4-carboxylate
    9.
    发明授权
    Diastereomers of 1-(isopropoxycarbonyloxy)ethyl 3-cephem-4-carboxylate 失效
    3-头孢烯-4-羧酸1-(异丙氧基羰基氧基)乙酯的非对映异构体

    公开(公告)号:US5461043A

    公开(公告)日:1995-10-24

    申请号:US940367

    申请日:1992-09-03

    CPC分类号: C07D501/00

    摘要: Enterally absorbable diastereomers of 1-(isopropoxycarbonyloxy)ethyl (6R,7R)-7-[2-(2-aminothiazol-4-yl)-2-(Z)-(methoxyimino)acetamido]-3-(methoxymethyl)-3-cephem-4-carboxylate of the formula I ##STR1## and their physiologically acceptable salts and also diastereomerically pure salts of the compounds of the formula II ##STR2## where HX is a mono- or polybasic acid and where X is an inorganic or organic physiologically acceptable anion, and a process for the preparation of these compounds of the formula I or II, which comprises first precipitating the more sparingly soluble diastereomer of the formula IV in the mixing together of 1 equivalent of a solution of the diastereomer mixture of the formula III with 0.2-2 equivalents of a solution of the acid component HY and separating it off by filtration, then precipitating the more readily soluble diastereomer of the formula IV from the filtration solution, it being possible for the acid component HY to be identical or different in the consecutive partial steps and any desired sequence of addition of different acid components HY being possible, and optionally further purifying the obtained salts by crystallization, are described.

    摘要翻译: 1-(异丙氧羰基氧基)乙基(6R,7R)-7- [2-(2-氨基噻唑-4-基)-2-(Z) - (甲氧基亚氨基)乙酰氨基] -3-(甲氧基甲基)-3 式I的化合物 - 头孢烯-4-羧酸酯及其生理学上可接受的盐以及式II化合物的非对映体纯盐,其中HX是单或多元酸,其中X是无机或有机的 生理上可接受的阴离子,以及制备这些式I或II化合物的方法,其包括首先将式IV的较微溶的非对映体沉淀在1当量的式(I)的非对映体混合物的溶液中, III与0.2-2当量的酸组分HY的溶液并通过过滤分离,然后从过滤溶液中沉淀出更容易溶解的式IV的非对映异构体,酸组分HY可能相同或不同 在一起 描述了部分步骤和任何期望的不同酸组分HY的加入顺序是可能的,并且任选地通过结晶进一步纯化得到的盐。